#USA #Radnor #Kessler Topaz Meltzer #Investor Alert #ADMA Biologics

Investor Alert: Legal Options for ADMA Biologics Investors

Kessler Topaz Meltzer & Check, LLP, a prominent law firm specializing in securities litigation, has recently announced its commitment to assist investors affected by the recent turmoil surrounding ADMA Biologics, Inc. Investors who acquired ADMA’s stock during the specific period covering August 9, 2024, to March 25, 2026, may be eligible to participate in a securities fraud class action lawsuit filed in the District Court of New Jersey.

Background of the Lawsuit

The firm’s alert came in response to significant developments in the financial condition of ADMA Biologics, which is publicly traded on NASDAQ under the ticker ADMA. The class action lawsuit was filed on behalf of individuals who purchased ADMA’s securities based on inaccurate and misleading information about the company’s revenue figures and internal controls. Investors have until August 10, 2026, to apply for lead plaintiff status.

Key Allegations

The complaint alleges severe misstatements and omissions related to the company’s financials, stating that:
1. ADMA Biologics had undisclosed related party transactions that compromised its financial integrity.
2. The company engaged in channel stuffing, artificially inflating revenue figures to meet sales expectations.
3. Deficiencies existed in their internal controls, raising concerns about the reliability of financial reports.

These allegations paint a picture of a company that may have manipulated its financial performance, leading to misguided investor confidence.

Impact on Investors

Following the publication of a critical report by Culper Research on March 24, 2026, ADMA Biologics’ stock experienced a substantial decline, falling by $3.96 or approximately 29.1% over two trading days. The report detailed that two executives from a key distributor corroborated claims of revenue manipulation to bolster apparent growth figures.

For investors, this steep drop in stock price not only signifies financial loss but poses questions regarding the viability of their investments in ADMA Biologics. In light of this, Kessler Topaz Meltzer & Check, LLP encourages affected individuals to explore their legal rights.

The Path Forward for Investors

The firm offers a clear course of action for those impacted:

• - File for Lead Plaintiff Status: Investors who believe they have a significant financial stake can nominate themselves as lead plaintiffs by the August 10 deadline.
• - Legal Consultation: Kessler Topaz Meltzer & Check, LLP provides free consultations to discuss potential legal options without any financial obligation. Their fees are contingent on successful recovery, ensuring that out-of-pocket expenses are managed effectively for clients.

Conclusion: Urgency to Act

Given the complexities of securities litigation and the tight deadlines, it's essential for ADMA Biologics investors to act promptly. Engaging with a qualified legal team can unravel the intricacies of these allegations and potentially lead to recovery for losses incurred due to alleged fraudulent activities. Kessler Topaz Meltzer & Check, LLP remains a proactive resource for investors seeking guidance and support during this challenging time.

For more information on filing or participation in the class action lawsuit, investors can visit the firm's website or contact attorney Jonathan Naji directly. The firm remains committed to advocating for the rights of individual and institutional investors in the face of alleged corporate misconduct.